Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2024-10-30 Report Publication Anno…
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024
Report Publication Announcement Classification · 99% confidence The document is very short (1867 characters) and its primary purpose is to announce *when* the company (OPKO Health, Inc.) will report its Third Quarter 2024 Financial Results (on November 7, 2024). It explicitly states, "Attached hereto is a report on *OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024.*" and references a PDF file. This structure—announcing the publication of results rather than containing the full results or management discussion—fits the definition of a Report Publication Announcement (RPA). It is not the Earnings Release (ER) itself, nor is it the full Interim Report (IR).
2024-10-30 English
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
Regulatory Filings Classification · 99% confidence The document is a press release issued by ModeX Therapeutics (a subsidiary of OPKO Health) announcing the receipt of additional funding from BARDA for the development of multispecific antibodies. This type of corporate announcement regarding financing, grants, or contract awards is classified as a Capital/Financing Update (CAP) as it details the company's capital structure and funding activities.
2024-10-07 English
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
Report Publication Announcement Classification · 98% confidence The document is very short (1792 characters) and explicitly states, "Attached hereto is a report on*ModeX …* *20241007PR_isa.pdf*". This structure—a brief filing announcing the publication of an attached or linked report—fits the definition of a Report Publication Announcement (RPA). It is not the full report itself (like 10-K or IR). The filing is made to the Israel Securities Authority (ISA) and Tel Aviv Stock Exchange (TASE) under immediate report regulations.
2024-10-07 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing Classification · 100% confidence The document explicitly displays the header "FORM 4" and includes sections detailing "Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned" and "Derivative Securities Acquired, Disposed of, or Beneficially Owned." Form 4 is the standard SEC filing used by corporate insiders (directors, officers, or 10% owners) to report changes in their beneficial ownership of the company's securities. This directly corresponds to the definition of Director's Dealing (insider trades). Although the document describes transactions involving convertible notes, the core purpose and format are that of an insider transaction report, which maps to the 'DIRS' code.
2024-09-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing Classification · 95% confidence The document explicitly mentions 'Form 4' and refers to 'related party transaction'. Form 4 filings in the US context typically relate to insider ownership changes, which often overlap with director/executive transactions. However, the document is a regulatory filing submitted to the Israel Securities Authority and Tel Aviv Stock Exchange, referencing US securities laws ('foreign private issuer'). The content is a notification that an attachment ('Form 4 – related party transaction') is included. This structure—a brief announcement pointing to a specific transaction report—is characteristic of insider trading or director dealing disclosures. Given the options, 'Director's Dealing (DIRS)' is the most appropriate category for reports detailing personal share transactions by executives, even if the specific form cited is Form 4 (which usually reports changes in beneficial ownership, often triggered by transactions). Since the document is short and announces an attached report, it could potentially be RPA/RNS, but the specific subject matter (Form 4/related party transaction/insider activity) strongly points to DIRS.
2024-09-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing Classification · 100% confidence The document explicitly contains the header "FORM 4" and details transactions made by reporting persons (Phillip Frost, M.D., ET AL) related to securities of OPKO Health, Inc. (OPK). Form 4 is the standard SEC filing used to report changes in beneficial ownership of securities by insiders (directors, officers, or 10% owners) following a transaction. This directly corresponds to insider trading reports, which are classified under 'Director's Dealing' (DIRS) in the provided schema, as it reports personal share transactions by company directors and executives.
2024-09-28 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.